EANS-Adhoc: Sanacorp Pharmaholding AG / Sanacorp disposes of Anzag investment

ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement.

18.10.2010

The pharmaceutical wholesale company Sanacorp Pharmahandel GmbH ("Sanacorp GmbH"), which is indirectly owned by Sanacorp Pharmaholding Aktiengesellschaft via its 50 percent interest in the Italian holding company Sanastera S.p.A., Bologna, signed an agreement on October 18th., 2010 stipulating the sale of approximately 24.99% in the capital stock of Andreae-Noris Zahn AG, Frankfurt (WKN 504700/ISIN DE0005047005). Acquirer is an investment company of the Alliance Boots Group. The implementation of the share purchase agreement is subject to the responsible cartel authorities´ approval.

The purchase price agreed per share is EUR 26.00. Sanacorp GmbH will thus receive cash flows of more than EUR 69 million expected to be used for the settlement of liabilities.

Sanacorp Pharmaholding AG

The Management Board

end of announcement euro adhoc

issuer: Sanacorp Pharmaholding AG Semmelweisstraße 4 D-82152 Planegg phone: +49 (0)89 8581 239 FAX: +49 (0)89 8581 445 mail: ir@sanacorp.de WWW: http://www.sanacorp.de sector: Wholesale ISIN: DE0007163131 indexes: CDAX, Classic All Share

stockmarkets: free trade: Berlin, Hamburg, Stuttgart, Düsseldorf, regulated dealing:
München, regulated dealing/general standard: Frankfurt language: English

Rückfragen & Kontakt:

Dr. Thomas Strieder
Phone: +49(89) 8581 494
E-Mail: t.strieder@sanacorp.de

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS | OTB0028